Worldwide access to Paxlovid remains inequitable

In a Think Global Health article, IHME staff examine the barriers to acquiring the antiviral Paxlovid, which can greatly reduce the chance of COVID-19 hospitalizations and deaths. Low- and middle-income nations must contend with licensing dilemmas, lack of supplies, and high costs to gain access to Paxlovid. “This would be similar to the […]